Buy Waylivra (volanesorsen) Online For Sale
$10,781.00
DISEASE INDICATIONS: Familial chylomicronemia syndrome (FCS)
MANUFACTURER: Akcea Therapeutics Ireland Limited
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Waylivra is a new RNA-targeted therapy that aims to inhibit the production of a protein that is key to fat metabolism, called ApoC-III, in order to lower triglyceride levels and reduce the associated health risks of familial chylomicronemia syndrome (FCS). Waylivra is administered by subcutaneous injection once a week, in conjunction with a low-fat diet and other lipid-lowering therapies as needed, and was approved by the US FDA in 2019.